<DOC>
	<DOCNO>NCT01368211</DOCNO>
	<brief_summary>The PRESS trial single-center , two-part , randomized cross-over pilot study Copenhagen evaluate 1 ) safety performance Mirasol-treated untreated platelet product store 2-4 day 7-days Platelet Additive Solution ( PAS ) 2 ) correlation TEG® parameter platelet count increment platelet transfusion thrombocytopenic subject .</brief_summary>
	<brief_title>Mirasol-Treated Platelets - ( Pathogen Reduction Extended Storage Study )</brief_title>
	<detailed_description>1 . To evaluate thrombocytopenic subject efficacy safety platelet treat Mirasol Pathogen Reduction Technology ( PRT ) Platelet Additive Solution . The following safety efficacy measure compare Mirasol treat untreated platelet store 2-4 day store 7 day : - Thrombelastography ( TEG® ) parameter : reaction time R , alpha angle α maximal amplitude ( MA ) - Platelet Count Increment Corrected Count Increment - Time next platelet transfusion - Incidence transfusion relate ( serious ) adverse event - Incidence severity bleeding 2 . To evaluate use TEG® parameter measure platelet transfusion efficacy evaluate correlation TEG® parameter platelet Corrected Count Increments platelet transfusion thrombocytopenic subject .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Male female age 18 year old . Have thrombocytopenia expect develop thrombocytopenia require least 3 platelet transfusion . Woman child bear potential must negative serum urine pregnancy test within 72 hour randomization . Subjects must sign date Informed Consent Form perform protocol related procedure . History hypersensitivity reaction riboflavin metabolite . History refractoriness platelet transfusion ( define 2 successive CCI1hr &lt; 5000 ) presence human leukocyte antigen ( HLA ) antibodies positive lymphocytotoxicity previously document alloimmunization . Previous exposure PRTtreated platelet concentrate . Active bleed require one red cell concentrate transfusion ( i.e . grade 3 4 bleeding accord WHO bleed assessment scale Appendix 1 ) . Exposure investigational product , within 30 day randomization . Splenomegaly ( presence palpable spleen whose border could felt 4 cm costal margin ) splenectomy . History diagnosis Immune/Idiopathic Thrombocytopenic Purpura ( ITP ) , Thrombotic Thrombocytopenia Purpura ( TTP ) , Haemolytic Uremic Syndrome ( HUS ) . Use prohibited medication ( see section 5.5 ) . Pregnant lactating female . Any medical condition treatment would expect compromise effectiveness platelet transfusion would interfere expect platelet count increment . Any medical condition would compromise participation subject study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Mirasol</keyword>
	<keyword>Thrombocytopenic</keyword>
	<keyword>Pathogen reduction</keyword>
	<keyword>Platelets</keyword>
	<keyword>Thromboelastography</keyword>
	<keyword>CCI</keyword>
	<keyword>Corrected Count Increment</keyword>
</DOC>